U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H17BrN4.ClH
Molecular Weight 333.655
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESR-1150 HYDROCHLORIDE

SMILES

Cl.CN(C)C1=CC=C(Br)C(N=C2NCCN2)=C1C

InChI

InChIKey=QTAUWYULRRTZNV-UHFFFAOYSA-N
InChI=1S/C12H17BrN4.ClH/c1-8-10(17(2)3)5-4-9(13)11(8)16-12-14-6-7-15-12;/h4-5H,6-7H2,1-3H3,(H2,14,15,16);1H

HIDE SMILES / InChI

Molecular Formula C12H17BrN4
Molecular Weight 297.194
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 00:36:48 GMT 2023
Edited
by admin
on Sat Dec 16 00:36:48 GMT 2023
Record UNII
P2BY9PUC48
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ESR-1150 HYDROCHLORIDE
Common Name English
1,3-BENZENEDIAMINE, 4-BROMO-N3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)-N1,N1,2-TRIMETHYL-, HYDROCHLORIDE (1:1)
Systematic Name English
4-BROMO-3-(IMIDAZOLIDIN-2-YLIDENEAMINO)-N,N,2-TRIMETHYL-ANILINE HYDROCHLORIDE
Systematic Name English
ESR 1150CL
Code English
Code System Code Type Description
CAS
850715-60-5
Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
PRIMARY
PUBCHEM
140120264
Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
PRIMARY
FDA UNII
P2BY9PUC48
Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
PRIMARY
CLINICAL_TRIALS.GOV
ESR-1150-CL
Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
PRIMARY Official Title: Administration of ESR 1150 CL in Ascending Doses of 0.5, 1, 2, 4 and 8 mg in an Open, Group Comparison and Placebo-controlled Design (Placebo Randomised Double Blind in the Dose Groups) for the Assessment of Safety, Tolerability (Maximum Tolerated Dose, MTD), Pharmacokinetics and Pharmacodynamics in 5 Groups of 8 Female and 5 Male Healthy Subjects, and 4 mg Additionally in Fed State, in a Cross Over Design. Safety, Tolerability and Pharmacokinetics of MTD/4, MTD/2 and MTD in 6 Healthy Male Subjects, Identified as CYP2D6 and/or "Spartein" Poor Metabolizers, in a 3-fold Cross Over, Open Study.